Israel Englander Chinook Therapeutics, Inc. Transaction History

Millennium Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $5.67 Million - $11.7 Million	303,712 Added 122.24%	552,166 $21.2 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $4.14 Million - $5.15 Million	-192,284 Reduced 43.63%	248,454 $5.75 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $778,156 - $1.14 Million	41,769 Added 10.47%	440,738 $11.5 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $13.8 Million - $18.4 Million	-786,264 Reduced 66.34%	398,969 $7.84 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $4.65 Million - $6.45 Million	386,695 Added 110.34%	737,139 $12.1 Million
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $3.36 Million - $5.29 Million	-314,032 Reduced 47.26%	350,444 $5.72 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $4.06 Million - $5.24 Million	352,915 Added 113.27%	664,476 $8.48 Million
Q2 2021 Aug 16, 2021	SELL	$13.6 - $18.98 $1.33 Million - $1.86 Million	-97,926 Reduced 23.91%	311,561 $4.4 Million
Q1 2021 May 17, 2021	BUY	$14.17 - $19.11 $4.38 Million - $5.91 Million	309,154 Added 308.13%	409,487 $6.36 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $1.19 Million - $2.1 Million	100,333 New	100,333 $1.59 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.